Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06302140 Recruiting - Advanced Cancer Clinical Trials

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Start date: February 28, 2024
Phase: Phase 1
Study type: Interventional

This study will determine how nanatinostat is absorbed, modified, and removed from the body (Part A), the amount of nanatinostat that becomes available to the body (Part B), and will evaluate the safety and tolerability of nanatinostat (Part C) in patients with advanced cancers.

NCT ID: NCT06302062 Recruiting - Clinical trials for Advanced Solid Tumor

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

TAL-T
Start date: June 6, 2023
Phase: Phase 1
Study type: Interventional

A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection. To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.

NCT ID: NCT06299839 Recruiting - Clinical trials for Advanced Solid Tumors

PAS-004 in Patients With Advanced Solid Tumors

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: - How well participants are able tolerate different doses of PAS-004, and - What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose, followed by one week observation, then once a day during the study, in 28-day cycles. Participants will continue on daily PAS-004 for up to 2 years, or until: - They decide to withdraw from the study, or - They experience unacceptable side effects, or - Their disease progresses, or another illness interferes with taking the study drug, or - The sponsors stops the study.

NCT ID: NCT06298058 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Start date: March 12, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).

NCT ID: NCT06297642 Recruiting - Clinical trials for Advanced Malignant Neoplasm

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.

NCT ID: NCT06297629 Not yet recruiting - Clinical trials for Allogeneic Stem Cell Transplantation

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Start date: July 31, 2024
Phase: Phase 2
Study type: Interventional

To learn if ASTX727 given alone or in combination with donor lymphocyte infusion (DLI) can help to control certain types of hematological neoplasms (blood-based cancers) after a stem cell transplant.

NCT ID: NCT06297525 Not yet recruiting - Solid Tumor Clinical Trials

Study of STP938 in Advanced Solid Tumours

Start date: September 2024
Phase: Phase 1
Study type: Interventional

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

NCT ID: NCT06297187 Active, not recruiting - Clinical trials for Condylomata Acuminata

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

Start date: February 23, 2024
Phase:
Study type: Observational

The study is a single arm, retrospective, single-center, post market registry. The purpose of this Registry is to collect data to demonstrate the safety and performance of CUSA® for the treatment of Vulvar Intraepithelial Neoplasia (VIN) and condyloma acuminata.

NCT ID: NCT06293651 Not yet recruiting - Clinical trials for Locally Advanced or Metastatic Solid Tumors

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.

NCT ID: NCT06292897 Recruiting - Obesity Clinical Trials

Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

OBESITA'&PCa
Start date: March 20, 2023
Phase:
Study type: Observational

Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI > 27.5) and non-severely overweight/normoweight (BMI < 27.5) patients affected by prostate carcinoma. ii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients. iii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and/or deregulation of relevant oncogenic pathways.